iPSC-Derived CAR T Cells for Off-the-Shelf Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR T cell therapies are expensive, laborious, and logistically challenging due to their autologous nature, requiring individualized blood apheresis and complex T cell development, which complicates the generation of effective 'off-the-shelf' cancer treatments.
Innovation Solution
Methods for generating phenotypically defined, functional T cells or NK cells expressing a chimeric antigen receptor (CAR) from pluripotent stem cells, such as embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs), which can be used as 'off-the-shelf' products, overcoming the limitations of traditional CAR T cell production by using naïve and memory T cells as starting material and employing specific differentiation protocols.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If autologous CAR T cell therapy is used, then patient-specific cancer treatment effectiveness is improved, but manufacturing complexity and cost increase
Solution Approach 1:
The patent uses induced pluripotent stem cells (iPSCs) as a copyable source to generate CAR T cells. Instead of requiring individual patient T cells, the invention creates iPSC lines that can be expanded and differentiated into CAR T cells for multiple patients, thereby reducing manufacturing complexity while maintaining treatment effectiveness through standardized protocols
Solution Approach 2:
The patent develops universal iPSC-derived CAR T cell products that can be used for multiple recipients. The iPSC technology enables a single cell line to serve multiple therapeutic purposes and multiple patients, transforming the autologous approach into an allogeneic system that maintains effectiveness while simplifying manufacturing
2Reliability
If autologous CAR T cell therapy is used, then patient-specific treatment is improved, but production time and logistics challenges increase
Solution Approach 1:
The patent performs preliminary actions by establishing iPSC lines and differentiating them into CAR T cells in advance, before actual treatment is needed. This allows for pre-manufacturing of therapeutic cell products that can be stored and rapidly deployed when clinical need arises, dramatically reducing production time compared to on-demand autologous manufacturing
Solution Approach 2:
By using iPSCs that can be cryopreserved and transported, the invention enables the therapeutic product to be prepared in advance at centralized facilities and shipped to treatment centers, eliminating the time-consuming logistics of coordinating individual patient blood collection, processing, and infusion scheduling
3Power
If CAR expression is introduced to redirect T cells, then cancer killing potential is improved, but T cell differentiation complexity increases
Solution Approach 1:
The patent uses iPSCs as an intermediary system to generate CAR T cells. Rather than directly modifying patient T cells through complex differentiation protocols, the invention employs iPSCs that naturally differentiate into T cell lineages, providing a simplified pathway to generate functional CAR T cells with desired differentiation characteristics
Solution Approach 2:
The patent controls T cell differentiation parameters by adjusting culture conditions, cytokine concentrations, and temporal profiles during iPSC differentiation. By systematically optimizing these parameters, the invention achieves consistent generation of CAR T cells with appropriate phenotypic and functional characteristics despite the inherent complexity of T cell development
4Adaptability or versatility
If iPSCs are used to generate CAR T cells, then off-the-shelf product availability is improved, but T cell differentiation control becomes more challenging
Solution Approach 1:
The patent implements dynamic control of T cell differentiation by using time-varying culture conditions, including staged cytokine additions, changing media compositions, and temporal progression through defined differentiation stages. This dynamic approach enables precise control over CAR T cell development from iPSCs while maintaining the flexibility needed for off-the-shelf manufacturing
Solution Approach 2:
The patent incorporates feedback mechanisms to monitor and adjust differentiation parameters during iPSC-to-CAR-T-cell conversion. By measuring intermediate markers and functional characteristics at various stages, the invention optimizes differentiation protocols to ensure consistent production of high-quality CAR T cells suitable for off-the-shelf products
Data Source
AI summary
Methods for preparing T cells or NK cells expressing a chimeric antigen receptor (CAR) is described. The methods entail: isolating a population of T cells, generating induced pluripotent stem cells (iPSCs) from the T cells, introducing a nucleic acid molecule encoding a CAR into the iPSCs to create CAR iPSCs; and differentiating the CAR iPSCs into CAR T cells or CAR NK cells.